Puma Biotechnology Expands Neratinib Access to HER2+ Breast Cancer Patients Ineligible for Clinical Trials

Puma Biotechnology Expands Neratinib Access to HER2+ Breast Cancer Patients Ineligible for Clinical Trials
Women with HER2-positive breast cancer or HER-mutated cancers who cannot participate in any PB272 (neratinib) clinical trial may now receive the investigational drug under the expanded access program (EAP) initiated by Los Angeles-based Puma Biotechnology. The U.S. Food and Drug Administration (FDA) lets drugmakers provide pharmaceuticals to seriously ill patients who do not quality for controlled trials of a drug because

Knowledge is power when living with breast cancer.

Get access to the web’s leading Breast Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *